Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TET3 | O43151 | 1/20 | 0.45 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.45 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654813 | 0.88 | KMT2A (0.59) | KMT2AMEN1TSHRSTSALOX15 | |
| SCHEMBL653532 | 0.88 | KMT2A (0.54) | KMT2AMEN1TSHRSTSALOX15 | |
| SCHEMBL4629887 | 0.87 | TSHR (0.49) | TSHRALOX15ATMOPRD1OPRK1 | |
| SCHEMBL6543780 | 0.87 | TSHR (0.63) | KMT2ATSHRALOX15ATMTET3 | |
| SCHEMBL23660780 | 0.86 | BACE1 (0.53) | KMT2ATSHRSTSALOX15ATM | |
| SCHEMBL26372781 | 0.86 | GPR119 (0.52) | KMT2AMEN1TSHRALOX15ATM | |
| SCHEMBL654744 | 0.86 | KMT2A (0.52) | KMT2AMEN1TSHRSTSALOX15 | |
| SCHEMBL10447211 | 0.85 | TSHR (0.48) | KMT2AMEN1TSHRSTSALOX15 | |
| SCHEMBL31158334 | 0.85 | TSHR (0.48) | KMT2AMEN1TSHRSTSALOX15 | |
| SCHEMBL4431260 | 0.85 | KMT2A (0.51) | KMT2AMEN1TSHRSTSALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867720-B | Heteroaryl derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-4092019-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-114867720-A | Heteroaryl derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2272517-B1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-10-01 | — | — | EP | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | KMT2A 3363/4885MEN1 3071/4885TSHR 3177/4885 |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | KMT2A 4480/4885MEN1 4167/4885TSHR 1422/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | KMT2A 4568/4885MEN1 4716/4885TSHR 972/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | KMT2A 4640/4885MEN1 4609/4885TSHR 1180/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | KMT2A 4568/4885MEN1 4716/4885TSHR 972/4885 |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | PTPN11, PTPN1, PTPN7 | KMT2A 1292/4885MEN1 1790/4885TSHR 2878/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | KMT2A 1082/4885MEN1 4673/4885TSHR 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.